Home > Healthcare > Medical Devices > Diagnostic Devices > Antimicrobial Resistance Diagnostics Market

Antimicrobial Resistance Diagnostics Market Trends

Report ID: GMI12145
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

Antimicrobial Resistance Diagnostic Market Trends

The rise in innovations in diagnostic technologies, including the introduction of polymerase chain reaction (PCR) and next-generation sequencing, has enabled rapid and accurate detection of resistant bacteria, further driving the growth of the antimicrobial resistance (AMR) diagnostic market. Moreover, the increasing shift towards point-of-care testing, which allows for immediate results and faster decision-making in treatment, is anticipated to boost demand for AMR diagnostics, thus propelling market growth.

For instance, in June 2023, Sysmex Corporation launched a testing system in Europe for the rapid detection of antimicrobial susceptibility. The system detects the presence or absence of bacteria and assesses antimicrobial effectiveness using urine samples from patients suspected of having urinary tract infections (UTIs). Consequently, various factors—such as rising infection rates, heightened public awareness, technological advancements, supportive government initiatives, and a growing emphasis on personalized medicine—are driving market growth.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global antimicrobial resistance diagnostics industry was valued at USD 4.4 billion in 2023 and is estimated to grow at a 6.3% CAGR from 2024 to 2032, driven by the increasing prevalence of antibiotic-resistant infections.

The kits & reagents segment dominated the market with USD 2.8 billion in 2023 due to their essential role in the early and accurate identification of resistant bacterial strains, which helps reduce inappropriate antibiotic use.

The U.S. antimicrobial resistance diagnostics industry is expected to grow at a 6.2% CAGR, reaching USD 3.1 billion by 2032, supported by government initiatives like CARB and ARSI.

Key players in the industry include Abbott Laboratories, Accelerated Diagnostics, USA, Alifax, Bio-Rad Laboratories, BioMerieux, Beckman Coulter, Becton, Dickinson and Company, and F. Hoffmann-La Roche.